NEWS & EVENTS
March 18, 2022
Michigan Medicine Laboratories will be exhibiting at USCAP this month. The 11th annual meeting runs from March 19-24, 2022 in Los Angeles, CA. Be sure to stop by booth 633 and grab a go blue football!
February 2, 2022
The West Ann Arbor Blood Draw center located at 380 Parkland Plaza, Suite 130, Ann Arbor, MI 48103 will be closing early at 5:00pm on Wednesday, February 2nd and Thursday, February 3rd. For more information about the blood draw site, please visit West Ann Arbor Health Center | MLabs (umich.edu)
August 18, 2021
MLabs now offers new approved therapy with KEYTRUDA through the PD-L1 (22C3 Assay). KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. This FDA approved companion diagnostic for KEYTRUDA to evaluate triple-negative breast cancer patients.
Featured Test (NEW)
Myeloid NGS Panel
This test is intended for the molecular evaluation of myeloid neoplasms including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemias (AML), mastocytosis and myeloid neoplasms with eosinophilia and gene rearrangement.
NGS Solid Tumor Panel
Molecular testing of solid tumor neoplasms - particularly advanced-stage cancer. This DNA and RNA based, NGS test targets 50 actionable genes (35 mutations, 19 amplifications, 21 - fusions). Requires <1mm2 of tissue (as little as 100 tumor cells) and a low 3% QNS rate.
Erdafitinib (Balversa™) is an FGFR-inhibitor that is FDA-approved for the treatment of metastatic urothelial cancers harboring susceptible mutations or translocations involving FGFR2 or FGFR3.
NR4A3 (9q22-9q31) Rearrangement (FISH)
NR4A3 encodes an orphan nuclear receptor. Rearrangements of NR4A3 occur in more than 80% of extraskeletal myxoid chondrosarcoma (EMC) as well as in salivary acinic cell carcinoma (AciCC), driving tumorigenesis.
NEW TREATMENT OPTION FOR METASTATIC BREAST CANCER
MLabs offers NGS Solid Tumor Panel and Single gene test to detect PIK3CA for FDA approved therapy alpelisib (Piqray®).
TFE3 Rearrangement (FISH)
Detecting rearrangements involving the TFE3 gene region (Xp11.2) via fluorescence in situ hybridization (FISH) to qualitatively assess for the presence of TFE3 translocations that are associated with certain subtypes of renal cell carcinoma. Testing for TFE3 gene rearrangement may aid in the diagnosis and classification of renal tumors.